Search Results
Your search for The ASCO ,The ASCO matches 20588 pages
Showing 7851 - 7900David H. Gutmann, MD, Receives Neuro-Oncology Award
The Society for Neuro-Oncology and the Section on Tumors of the American Association of Neurological Surgeons/Congress of Neurological Surgeons recently named David H. Gutmann, MD, PhD, as recipient of the Abhijit Gua Award. This award is presented annually to an investigator who has achieved...
Clinical Happenings and Highlights at the 2019 ASH Annual Meeting
The 61st American Society of Hematology (ASH) Annual Meeting & Exposition is being held December 7–10, 2019, at the Orange County Convention Center in Orlando. Be sure to visit The ASCO Post in the exhibit hall (booth 2429, Harborside) and watch interviews with experts being filmed there live....
The Anesthesia Era: 1845–1875
The text and photograph on this page are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era: 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and...
Oncology Massage Therapy for Chemotherapy-Induced Peripheral Neuropathy
Oncology massage therapy might be a helping hand for patients suffering from chronic chemotherapy-induced peripheral neuropathy, according to data presented at the 2019 Supportive Care in Oncology Symposium.1 The results of the pilot study supported the premise that patients who received massages...
Final Overall Survival Results of IMpower131 Trial in Advanced Squamous NSCLC
In patients with stage IV squamous non–small cell lung cancer (NSCLC), those with high programmed cell death ligand 1 (PD-L1) expression treated with atezolizumab and chemotherapy experienced longer overall survival rates than those treated with chemotherapy alone. For those participants without...
First-Line Nivolumab Plus Ipilimumab in Special Populations With Non–Small Cell Lung Cancer
First-line therapy consisting of nivolumab plus ipilimumab showed a consistent safety profile in special populations with advanced non–small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung ...
Thomas Gajewski, MD, PhD, Receives 2019 ESMO Award for Immuno-Oncology
The European Society for Medical Oncology (ESMO) has selected Thomas Gajewski, MD, PhD, to receive the 2019 ESMO Award for Immuno-Oncology. The award is given in recognition of his groundbreaking work elucidating why some patients are resistant to immunotherapy and how to restore the anticancer...
Stanford Medicine Division of Oncology Welcomes Three New Faculty Members
The Stanford Medicine Department of Medicine is excited to welcome three faculty members to its Division of Oncology: Curtis Chong, MD, PhD; Fauzia Riaz, MD; and Shagufta Shaheen, MD. Each of these individuals brings an impressive record of academic pursuits focused on advancing care for and...
ACCC Presents Annual Achievement Award Posthumously to Arti Hurria, MD, FASCO
The 2019 Association of Community Cancer Centers (ACCC) Annual Achievement Award was presented posthumously to Arti Hurria, MD, FASCO, of City of Hope. The oncology community experienced a devastating loss with the untimely passing of Dr. Hurria in November 2018. Dr. Hurria was the George Tsai...
Christian A. Koch, MD, PhD, FACP, Joins Faculty at Fox Chase Cancer Center
Fox Chase Cancer Center announced the hiring of Christian A. Koch, MD, PhD, FACP, who will join the Department of Medicine, Section of Endocrinology, as Director and Professor. Dr. Koch comes to Fox Chase from the University of Tennessee, Memphis, where he served as Clinical Professor. Dr. Koch is ...
A Need for Human Connection Led to a Rewarding Career in Geriatric Oncology for Lodovico Balducci, MD
Older adults are the fastest-growing segment of our population, and more than 65% of patients with newly diagnosed cancer are 65 years of age or older. Although we now recognize the special needs of older patients with cancer, the field of geriatric oncology emerged quietly, with early growing...
An Oncologist’s Thoughtful Examination of Cancer and Personal Loss
“I could not have written this book when I was 30 years old. It is not because of any great discoveries I have made or research papers I have published since. It is because of the experience the intervening decades have given me as I cared for thousands of cancer patients and accompanied many to...
2019 Mary Pazdur Award for Excellence in Advanced Practice in Oncology
The Advanced Practitioner Society for Hematology and Oncology (APSHO) recently awarded the 2019 Mary Pazdur Award for Excellence in Advanced Practice in Oncology to Jody Pelusi, PhD, FNP, AOCNP (center). Dr. Pelusi is with HonorHealth Research Institute in Scottsdale. The award was presented...
Addressing the Obesity Epidemic and Barriers to Implementing Weight Management Programs for Cancer Survivors
Earlier this year, ASCO published the results of its new study on oncologists’ perceptions and practice behaviors regarding obesity, weight management, and related lifestyle factors in their patients both during and after cancer treatment.1 The findings from the online survey of 971 oncology...
ASCO Provides Guidance on Managing Osteoporosis in Cancer Survivors
Cancer survivors are at an increased risk of osteoporotic fractures due to the accelerated loss of bone mineral density as a result of their treatment. Bone loss from cancer therapy is faster and more severe than bone less from aging; rates of bone loss are up to sevenfold higher when they occur...
FDA Office of Hematology Oncology Products Reorganized, Renamed Office of Oncologic Diseases
As part of modernization plans approved in September 2019, the U.S. Food and Drug Administration (FDA) office responsible for reviewing applications for new and existing cancer therapies has reorganized and been renamed. The Center for Drug Evaluation and Research (CDER) Office of Hematology and...
ASH Names Recipients of Outstanding Abstract Achievement Awards
Each year, the American Society of Hematology (ASH) offers merit-based awards to support select trainees with high-achieving annual meeting abstracts who are chosen to present their work at the ASH Annual Meeting. Trainees include those who fall within one of the following categories: undergraduate ...
New Collaboration Offers Personalized Guidelines for Patients
Outcomes4Me Inc and the National Comprehensive Cancer Network® (NCCN®) recently announced a new collaboration to integrate the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer into the Outcomes4Me mobile application. The collaboration leverages Outcomes4Me’s...
Award Winners Named for 2019 San Antonio Breast Cancer Symposium
The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR) will honor two renowned researchers for their work in breast cancer at the 2019 SABCS, to be held December 10–14 in San Antonio. Myles Brown, MD, is the recipient of the 2019 AACR Distinguished ...
The World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the updated World Health Organization (WHO) classification of nodular lymphocyte-predominant Hodgkin lymphoma. For...
American Society of Hematology Honors Posthumously Stanley L. Schrier, MD, With 2019 Exemplary Service Award
The American Society of Hematology (ASH) recognized Stanley L. Schrier, MD, a Past ASH President and formerly Professor Emeritus of Medicine in Hematology at Stanford School of Medicine, California, with the 2019 Exemplary Service Award for his years of service and dedication to ASH and to...
MD Anderson Names New Senior Vice President and Chief Legal Officer
The University of Texas MD Anderson Cancer Center has named Allyson Hancock Kinzel, JD, as Senior Vice President and Chief Legal Officer, effective November 1, 2019. Ms. Kinzel takes on this new role leading legal and regulatory affairs after serving as Chief Legal Officer since 2018. She will...
Maximizing Benefit in the Treatment of Immune-Mediated Colitis
Immune-related colitis is the second most common toxicity associated with checkpoint inhibitors, affecting up to 40% of patients. The ASCO Post interviewed Yinghong Wang, MD, PhD, Director of Medication-Induced Colitis and Enteritis, Director of Fecal Microbiota Transplantation, and Associate...
Ethan Basch, MD, MSc, Receives ACCC Clinical Research Award
The Association of Community Cancer Centers (ACCC) 2019 Clinical Research Award was presented to Ethan Basch, MD, MSc, during the ACCC 36th National Oncology Conference held recently in Orlando, Florida. Dr. Basch is the Director of the Cancer Outcomes Research Program and Professor of Hematology...
Role of Physical Activity in Cancer Treatment and Survivorship
On October 16, 2019, an expert panel convened by the American College of Sports Medicine (ACSM)released updated guidance and recommendations on the role of physical activity and exercise in cancer prevention and survivorship. The panel was co-chaired by Kathryn Schmitz, PhD, MPH, of the Department...
Confirmation Hearing for FDA Commissioner Nominee Stephen Hahn, MD
On November 20, 2019, Stephen Hahn, MD, President Trump’s nominee to be the next Commissioner of the U.S. Food and Drug Administration (FDA), appeared before the Senate Health, Education, Labor, and Pension Committee and answered wide-ranging questions relating to the many important roles the...
American Society for Dermatologic Surgery Awards Eight Research Grants
The American Society for Dermatologic Surgery (ASDS) has announced eight grant recipients across three research programs to support its mission to foster, develop, and encourage investigative knowledge in dermatologic surgery. Jumpstart Research Seed Grants Three Jumpstart Research Seed Grants were ...
Pivotal Study Reports Positive Findings in Fourth-Line Setting for Advanced GIST
In a late-breaking, oral presentation at the European Society for Medical Oncology (ESMO) 2019 Congress, Margaret von Mehren, MD, presented results from INVICTUS, a pivotal phase III clinical study of ripretinib in patients with advanced gastrointestinal stromal tumor (GIST).1 Ripretinib is an...
City of Hope’s Michael Caligiuri, MD, Formally Appointed to Deana and Stave Campbell Physician-in-Chief Distinguished Chair
Michael A. Caligiuri, MD, President of City of Hope National Medical Center, in Duarte, California, has been appointed the Deana and Steve Campbell Physician-in-Chief Distinguished Chair in Honor of Alexandra Levine, MD. The position was created in honor of Dr. Levine, a City of Hope Professor of...
National Comprehensive Cancer Network Oncology Research Program Supports Clinical Trial for Lung Cancer
The National Comprehensive Cancer Network (NCCN®) Oncology Research Program (ORP) has announced plans to support a phase II randomized trial for lung cancer patients. The study is titled, “TH-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab in...
Selinexor/Dexamethasone in Refractory Multiple Myeloma: The STORM Has Arrived, but Does It Represent Climate Change?
The term “relapsed/refractory multiple myeloma” is often used to describe advanced myeloma that has progressed through primary or salvage therapy. The International Myeloma Working Group (IMWG) defined the term in 2011 as disease that is “nonresponsive while on salvage therapy or progresses...
ASCO Updates Breast Cancer Risk Reduction Guideline to Include Anastrozole
ASCO has updated a guideline on pharmacologic interventions for breast cancer risk reduction in postmenopausal women at increased risk of developing breast cancer.1 The original clinical practice recommendations for breast cancer risk reduction were published in 1999 and updated in 2002, 2009, and...
CDC Foundation Offers New Educational Resources to Prevent Infections in Patients With Cancer
The Centers for Disease Control and Prevention (CDC) Foundation commemorates the 10-year anniversary of the Preventing Infections in Cancer Patients (PICP) program by launching new resources that provide continued and improved support to patients with cancer undergoing chemotherapy. The new...
Prescribing Hope
“There is no medicine like hope, no incentive so great, and no tonic so powerful as expectation of something tomorrow.” –Orison Swett Marden I was informed that my patient, a 58-year-old man recently diagnosed with pancreatic cancer, and his wife were becoming impatient waiting for me in the exam...
Challenging the Global Community to Deliver Equitable Cancer Care for All
For Her Royal Highness Princess Dina Mired of Jordan, ensuring that every patient with cancer receives high-quality care is not an abstract goal—it is personal. Princess Dina saw firsthand the life-and-death differences that access to state-of-the-art oncology care makes in a patient’s life when...
CAR T-Cell Gene Therapy: Toxicities and Management Principles
“Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” —Marie Curie The ASCO Post is pleased to present Hematology ...
Friends of Cancer Research Launches ctDNA Pilot Project
Friends of Cancer Research (Friends) recently announced the launch of its latest project, ctMoniTR. This pilot project will aim to harmonize the use of circulating tumor DNA (ctDNA) to monitor treatment response in patients with cancer and test the feasibility of data comparison from different...
Project Socrates: An Educational Bridge From the FDA to the Public
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Jennifer J. Gao, MD, Acting Associate Director of Education in the OCE, and Richard Pazdur, MD, Director of ...
2019 State of Lung Cancer Report Released
More Americans than ever are surviving lung cancer. While the disease remains the leading cause of cancer deaths among both women and men, over the past decade, the survival rate has increased. A new report from the American Lung Association—the 2019 State of Lung Cancer—examines this promising...
MicroRNA Panel Could Aid in the Detection of Uveal Melanoma
A blood test could soon become a monitoring tool for the early detection of uveal melanoma. Stark et al discovered markers in the blood that can differentiate between a benign mole and a melanoma, while also determining whether the cancer has metastasized, according to findings they published in...
FDA Approves Givosiran for Acute Hepatic Porphyria
On November 20, the U.S. Food and Drug Administration (FDA) approved givosiran (Givlaari) for adults with acute hepatic porphyria, a genetic disorder resulting in the buildup of toxic porphyrin molecules which are formed during the production of heme. “This buildup can cause acute attacks, known...
FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis
On November 21, as part of Project Orbis—a collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada—the U.S. Food and Drug Administration (FDA) granted supplemental approval to acalabrutinib (Calquence) for the treatment of adults with chronic lymphocytic leukemia...
Two Societies Issue Statements on E-Cigarettes
Today, the American Cancer Society (ACS) announced an update to the organization’s position on e-cigarettes, and the American Medical Association (AMA) called for a total ban on all e-cigarette and vaping products that do not meet U.S. Food and Drug Administration (FDA) approval as cessation ...
Does Testosterone Replacement Therapy Benefit Young Male Cancer Survivors?
Young male cancer survivors may significantly benefit from testosterone replacement therapy—especially after testicular cancer. Research published by Walsh et al in PLOS Medicine looked at one of the most common late-onset side effects experienced by young male survivors—reduced levels of the male...
Boswellia
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, focus on the herbal extract...
Role of Voriconazole in Cutaneous Squamous Cell Carcinoma Development
For the last decade, medical experts have known that voriconazole—an antifungal medication used to prevent infections in patients with compromised immune systems—is linked to the development of particularly aggressive squamous cell carcinoma in skin exposed to ultraviolet (UV) rays. However, the...
Disparities in Culturally Competent Cancer Care
Many nonwhite minority cancer survivors place importance on seeing doctors who share or understand their culture, but are less likely than non-Hispanic whites to be able to see such physicians, according to a new study. The study, which is one of the first nationally-representative studies to...
Maximizing Benefit in the Treatment of Immune-Mediated Colitis
Immune-related colitis is the second most common toxicity associated with checkpoint inhibitors, affecting up to 40% of patients. The ASCO Post interviewed Yinghong Wang, MD, PhD, Director of Medication-Induced Colitis and Enteritis, Director of Fecal Microbiota Transplantation, and Associate...
FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell Lymphoma
On November 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Brukinsa) for adult patients with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma usually responds well to initial treatment, but eventually returns or ...
Reflections on Long-Term Outcomes With BRAF/MEK Inhibition in Advanced Melanoma
For the treatment of BRAF V600-mutated advanced melanoma, we now have three BRAF/MEK inhibitor combinations that are approved by the U.S. Food and Drug Administration: dabrafenib/trametinib, vemurafenib/cobimetinib, and encorafenib/binimetinib. Although the toxicity profiles for these combinations ...
